Investment analysts at Morgan Stanley began coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a report released on Monday,Briefing.com Automated Import reports. The brokerage set an "overweight" rating and a $46.00 price target on the stock. Morgan Stanley's price objective would indicate a potential upside of 32.34% from the stock's previous close.
Other equities analysts also recently issued reports about the company. Barclays started coverage on Hinge Health in a research note on Monday. They issued an "overweight" rating and a $43.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Hinge Health in a research report on Monday. They set a "buy" rating and a $52.00 price target on the stock. Needham & Company LLC assumed coverage on Hinge Health in a research note on Monday. They set a "buy" rating and a $47.00 target price for the company. Bank of America initiated coverage on shares of Hinge Health in a research report on Monday. They issued a "buy" rating and a $42.00 price target on the stock. Finally, KeyCorp began coverage on shares of Hinge Health in a research report on Monday. They issued an "overweight" rating and a $45.00 target price on the stock. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.00.
Get Our Latest Stock Analysis on HNGE
Hinge Health Stock Performance
Shares of HNGE opened at $34.76 on Monday. Hinge Health has a 52 week low of $33.42 and a 52 week high of $43.80.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.